UCB

UCB to Sell Neurology and Allergy Business in China

Belgium-headquartered biopharmaceutical company UCB is to sell its mature neurology and allergy business in China to Singapore-based asset management group CBC and investor Mubadala, based in Abu Dhabi, for $680 million.

News • Innovation

Artificial Intelligence for New Drug Design

Digital tools are a key to shortening the development of active pharmaceutical ingredients and thus market-ready drugs and therapies.

News

UCB Buys Handl, Partners Lacerta

Belgian biopharma UCB has announced two moves that will boost its gene therapy capabilities.

News

Portfolio Management

Top-Feature

INOSIM GmbH

Predictive Simulation in Pharma Production

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.